Cellphire Therapeutics, Inc., the global leader in long-term stabilization and storage of platelets, announced today the close of a $15 million Series A financing round led by Simcah Management.

Cellphire Therapeutics, Inc. is a biotechnology company developing next-generation therapeutics. The company is applying its proprietary cell stabilization technology to platelets, to develop lifesaving products. Its lead investigational product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire's technology has potential applications across a wide range of medical applications from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine. For more information, visit www.cellphire.com.

Cellphire Therapeutics, Inc. Closes $15 Million Series A Funding Round Led By Simcah Management

Description

Company Information

Funding Insights

Cellphire Therapeutics, Inc. Closes $15 Million Series A Funding Round Led By Simcah Management

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information